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ABSTRACT 
BACKGROUND AND AIMS 
One fourth of colorectal neoplasia is missed at screening colonoscopy, representing the main cause of 
interval colorectal cancer (CRC). Deep learning systems with real-time computer-aided polyp detection 
(CADe) showed high accuracy in artificial settings, and preliminary randomized clinical trials (RCT) 
reported favourable outcomes in clinical setting. Aim of this meta-analysis was to summarise available RCTs 
on the performance of CADe systems in colorectal neoplasia detection. 
METHODS 
We searched MEDLINE, EMBASE and Cochrane Central databases until March 2020 for RCTs reporting 
diagnostic accuracy of CADe systems in detection of colorectal neoplasia. Primary outcome was pooled 
adenoma detection rate (ADR), Secondary outcomes were adenoma per colonoscopy (APC) according to 
size, morphology and location, advanced APC (AAPC), as well as polyp detection rate (PDR), Polyp-per-
colonoscopy (PPC), and sessile serrated lesion per colonoscopy (SPC). We calculated risk ratios (RR), 
performed subgroup, and sensitivity analysis, assessed heterogeneity, and publication bias. 
RESULTS 
Overall, 5 randomized controlled trials (4354 patients), were included in the final analysis. Pooled ADR was 
significantly higher in the CADe groups than in the control group (791/2163, 36.6% vs 558/2191, 25.2%; 
RR, 1.44; 95% CI, 1.27-1.62; p<0.01; I2:42%). APC was also higher in the CADe group compared with 
control (1249/2163, 0.58 vs 779/2191, 0.36; RR, 1.70; 95% CI, 1.53-1.89; p<0.01;I2:33%). APC was higher 
for <5 mm (RR, 1.69; 95% CI, 1.48-1.84), 6-9 mm (RR, 1.44; 95% CI, 1.19-1.75), and >10 mm adenomas 
(RR, 1.46; 95% CI, 1.04-2.06), as well as for proximal (RR, 1.59; 95% CI, 1.34-1.88) and distal (RR, 1.68; 
95% CI, 1.50-1.88), and for flat (RR: 1.78 95% CI 1.47-2.15) and polypoid morphology (RR, 1.54; 95% CI, 
1.40-1.68). Regarding histology, CADe resulted in a higher SPC (RR, 1.52; 95% CI,1.14-2.02), whereas a 
nonsignificant trend for AADR was found (RR, 1.35; 95% CI, 0.74 – 2.47; p = 0.33; I2:69%). Level of 
evidence for RCTs was graded moderate. 
CONCLUSIONS 
According to available evidence, the incorporation of Artificial Intelligence as aid for detection of colorectal 
neoplasia results in a significant increase of the detection of colorectal neoplasia, and such effect is 
independent from main adenoma characteristics.  
Key Words: Artificial intelligence; Screening; Prevention; Quality. 
INTRODUCTION 
Interval colorectal cancer (CRC) represents one of the most dismal consequences of screening 
colonoscopy with an incidence of 0.5 to 1 per 1000 patient-years1,2. The main cause is represented by 
overlooked lesions that may be referred to recognition failure (when the endoscopist misses a lesion present 
on the screen) or incomplete mucosal exposure that depends on the complexity of the colorectal anatomy 
and/or suboptimal technique in the withdrawal phase of colonoscopy3–6. 
By addressing these pitfalls, artificial intelligence is expected to reduce the risk of miss rate and 
consequently of interval CRC7,8. In detail, the adoption of convoluted neural networks (CNN) or deep 
learning led to the technical feasibility of real-time computer-aided detection (CADe) capable of flagging the 
suspected lesion to the endoscopist with a visual and acoustic alarm. Different CNN systems are also able to 
alert the endoscopist any time the technical standard of withdrawal technique is suboptimal, ie, speed of 
withdrawal, inadequate level of cleansing, or slipping of the endoscope. 
 After successful artificial validation9, CADe systems have been applied in the  clinical setting to 
assess their benefit of improved detection in terms of adenoma detection rate (ADR) or adenomas per 
colonoscopy (APC), as well as possible harms such as deskilling of the endoscopist or time wasting due to 
false positive results10–12. Initial studies demonstrated favorable results on detection10–12, but were generally 
underpowered to assess the relationship between increased detection and lesion characteristics, such as polyp 
size, morphology, location or histology. In this regard, the miss rate of colorectal neoplasia at screening 
colonoscopy has been variably associated with small size, flat morphology, proximal location, and serrated 
histology in back to back studies3. In addition, there is uncertainty on whether the additional detection of 
neoplasia, namely an increase adenoma detection rate (ADR), is also associated with an increase in the 
detection of advanced adenomas, defined as either >10 mm or unfavorable histology13,14.  
 The aim of our systematic review and meta-analysis is to assess the relationship between the 
increased detection led by CADe and the main features of the detected lesions. 
MATERIALS AND METHODS 
This systematic review was reported according to Preferred Reporting Items for Systematic Reviews and 
Meta‐Analyses (PRISMA) guidelines15. 
Data sources and search strategy 
We performed a comprehensive literature search in MEDLINE, Cochrane Central Register of Controlled 
Trials (CENTRAL) and Embase (up to March 31, 2020) electronic databases to identify Randomized 
Clinical Trials (RCT) evaluating the role of CADe systems in lesion detection or mucosal exposure. A 
specialist with expertise in systematic reviews of randomized trials designed the search strategy (Appendix 
1A-C). Electronic searches were supplemented by manual searches of references of included studies and 
review articles. 
Selection process 
Two review authors (M.S., A.I.) independently screened the titles and abstracts yielded by the search against 
the inclusion criteria. Full reports were obtained for all titles that appeared to meet the inclusion criteria or 
where there was any uncertainty. Review author pairs then screened the full text and abstract reports and 
decided whether these met the inclusion criteria. The reasons for excluding trials were recorded. Neither 
review author was blinded to the journal titles or to the study authors or institutions. When there were 
multiple articles for a single study, we used the latest publication and supplemented it, if necessary, with data 
from the more complete version.  
Data extraction 
Using standardized forms, 2 reviewers (M.S., A.I.)  extracted data independently and in duplicate from each 
eligible study. Reviewers resolved disagreements by discussion. Unresolved disagreements were resolved by 
2 arbitrators (C.H., A.R.). Data extracted for each study included publication status, study design and 
location, number of centers involved, number of patients, patient characteristics (mean/median age, gender), 
colonoscopy indication, adenoma detection rate, polyp detection rate, number and characteristics (size, 
location, and histology) of detected polyps and withdrawal time. The corresponding authors of the included 
studies were asked for missing data. In the case of discrepancy or if data were missing, an attempt to contact 
the corresponding authors was done. 
Inclusion and exclusion criteria 
For the purpose of our meta-analysis, we screened all clinical studies for the following inclusion criteria:  
(1) Population: all adults (>18 years old) undergoing colonoscopy in nonemergency setting. 
(2) Intervention: colonoscopy with high-definition endoscopes implemented with real-time CADe 
systems.  
(3) Comparison: colonoscopy with high-definition endoscopes.  
(4) Outcome: adenoma and polyp detection rate.  
(5) Study design: only randomized controlled trials were considered.  
Exclusion criteria were as follows:  
(1) Essential information not available;  
(2) Studies not published as full text article; 




• Adenoma detection rate (ADR):  proportion of individuals undergoing a complete colonoscopy who 
had at least one adenoma detected (and removed).  
 
Secondary outcomes 
• Adenomas per colonoscopy (APC):  number of adenomas per colonoscopy, calculated by dividing 
the total number of adenomas detected by the total number of colonoscopies. APC was investigated 
according to lesion characteristics, namely size, morphology, location, and histology. 
• Polyp detection rate (PDR): proportion of individuals undergoing a complete colonoscopy who had 
at least one polyp detected.  
• Polyps per colonoscopy (PPC):  number of polyps per colonoscopy, calculated by dividing the total 
number of polyps detected by the total number of colonoscopies. PPC was investigated according to 
lesion characteristics, namely size, morphology, location, and histology. 
• Sessile serrated lesions per colonoscopy (SPC): number of sessile serrated lesions (SSLs) per 
colonoscopy, calculated by dividing the total number of sessile serrated lesions detected by the total 
number of colonoscopies. The definition of sessile serrated lesion adopted by the Authors was used 
for the purpose of our analysis. 
• Advanced adenomas per colonoscopy (AAPC): number of advanced adenomas per colonoscopy, 
calculated by dividing the total number of advanced adenomas detected by the total number of 
colonoscopies. 
• Withdrawal time: the time spent in inspecting the colonic mucosa as the endoscope is withdrawn 
during a colonoscopy. Biopsy or treatment time were excluded in all studies. 
 
Quality assessment 
Quality was assessed by the Cochrane risk bias tool for randomized studies. Two reviewers (M.S., A.I.) 
assessed quality measures for included studies and discrepancies were adjudicated by discussion.  
Data Synthesis and Analysis 
In individual trials, we estimated risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) 
for continuous ones, together with their 95% confidence intervals (95% CIs). When mean and standard 
deviation were not reported for continuous outcomes, we calculated these statistics from median and 
interquartile range, according to the methods described by Luo et al16 and Wan et al.17 We calculated pooled 
estimates using the DerSimonian and Laird random-effects model18.  
We assessed heterogeneity of intervention effects among primary studies using the Chi2 (Cochran Q) and I2 
statistics. We considered I2 cut-off points of 25%, 50%, and 75% as indicative of low, moderate, and high 
heterogeneity, respectively19. 
We conducted prespecified subgroup analyses for adenomas per colonoscopy and polyps per colonoscopy by 
colonic segment (right colon segement, transverse colon, left colon segment, or rectum), colonic site 
(proximal to splenic flexure or distal colon), size (<5 mm, 6-9 mm, >10 mm; and <10 mm, >10 mm), and 
morphology (polypoid or nonpolypoid). We estimated differences among subgroups by the Mantel-Haenszel 
test and heterogeneity using the Chi2 and I2 statistics.  
We planned sensitivity analyses by the leave-one-out approach for the primary outcomes (ie, adenoma 
detection rate and polyp detection rate) to investigate the influence of each individual trial on the overall 
effect estimate. We also performed sensitivity analysis for withdrawal time by excluding studies 
investigating systems which provide control on the endoscope withdrawal time.  
We explored publication bias using funnel plots. We rated the quality of evidence according to the Grades of 
Recommendation, Assessment, Development and Evaluation (GRADE) approach20. 
We performed leave-one-out sensitivity analyses using Stata (StataCorp LP). All other analyses were carried 
out using RevMan 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). 
RESULTS 
Study characteristics and quality 
The initial literature search resulted in 554 articles (Figure 1). A total of 6 RCTs10,11,21–24, all published 
between 2019 and 2020, tested the impact of CNN based systems on detection of colorectal neoplasia. One 
study24 was excluded because using a non-CADe CNN-based system focusing on withdrawal time and scope 
speed. Of the 5 included CADe-based RCTs,10,11,21–23 one coupled the CADe algorithm to CNN models 
developed to assess quality indicators (withdrawal time, withdrawal stability, and bowel preparation).22 
Different CADe systems characteristics are summarized in Supplementary Table 1. 
Most of the studies were conducted in China (n=4)11,21–23 and only 1 study came from Western countries 
(Italy)10. All but 1 study were single-center experiences. The objective assessment of risk of bias is reported 
in Supplementary Figure 1.  
The total number of participants included in the analysis was 4354 (2163 in the CNN and 2191 in the control 
group), and the individual study sample size ranged from 623 to 1058 patients. Study characteristics are 
comprehensively shown in Table 1. 
Adenoma and Polyp detection rate 
Based on the data reported by all the 5 studies, the overall ADR was significantly higher for the CADe group 
compared with the control group, respectively (791/2163, 36.6% vs 558/2191, 25.2%; RR, 1.44; 95% CI, 
1.27-1.62; p<0.01). All RCT reported a significant ADR increase. However, there was moderate 
heterogeneity (I2: 42%) in the level of the effect (Figure 2). Leave-one-out sensitivity analysis on ADR is 
reported in Supplementary Figure 2.  
The overall PDR was also significantly improved in CADe group compared with control group with 1089 
and 758 patients with at least one polyp out of 2163 and 2191 patients, respectively (50.3% vs 34.6%; RR, 
1.43; 95% CI, 1.34-1.53; p<0.01) with low level of heterogeneity (I2: 0%) across the 5 studies 
(Supplementary Fig. 3).  
We explored publication bias of both the outcomes using funnel plots resulting in no small-study effect 
(Supplementary Fig. 4). 
Adenoma, Sessile serrated lesions, and Polyps per colonoscopy 
The number of adenomas detected per colonoscopy (APC) was significantly higher in the CADe group 
compared with the control group (1249/2163, 0.58 vs 779/2191, 0.36, RR: 1.70; 95% CI, 1.53-1.89; p<0.01) 
with moderate level of heterogeneity (I2: 33%). The performance of CADe systems in significantly 
improving APC was confirmed irrespectively from adenoma size (RR <5 mm: 1.69; 95% CI, 1.48-1.84 vs 
RR 6-9 mm: 1.44, 95% CI, 1.19-1.75 vs RR >10 mm: 1.46, 95% CI, 1.04-2.06, Figure 3), location (RR 
proximal: 1.59 95% CI, 1.34-1.88 vs RR distal: 1.68; 95% CI, 1.50-1.88; Figure 4), and morphology (RR 
flat,1.78; 95% CI, 1.47-2.15 vs RR polypoid: 1.54; 95% CI, 1.40-1.68; Supplementary Fig. 5) (Table 2).  
Based on data of 3 studies 10,11,21, only a not statistically significant trend in the number of advanced 
adenomas detected was found in favor of CADe as compared with control group (116/1347, 0.09  vs 
71/1358, 0.05 RR: 1.35; 95% CI, 0.74 – 2.47; p: 0.33, I2: 69%).  
The number of sessile serrated lesions detected per colonoscopy (SPC) was significantly improved in the 
CADe group compared with the control group (109/1855, 0.06 vs 73/1876, 0.04, RR: 1.52; 95% CI, 1.14-
2.02; p<0.01) with low level of heterogeneity (I2: 0%) (Supplementary Fig. 6) across 4 studies10,21,21,23. 
Results of polyps per colonoscopy (PPC) and other per-polyps analysis were extensively reported in 
Supplementary Table 2. 
Withdrawal time 
No statistically significant difference between CADe and control groups was observed in term of mean 
withdrawal time (mean difference CADe vs control: 0.34 minutes,95%  CI,-0.10 – 0.78; p = 0.13) with high 
level of heterogeneity (I2: 97%). However, the heterogeneity level turn to be low (I2: 0%), if excluding in a 
sensitivity analysis the study in which the CADe systems play a direct role in influencing the withdrawal 
time22 (mean difference: 0.10; 95% CI, 0.02 – 0.18; p: 0.02) (Supplementary Fig. 7).  
Quality of evidence 
The quality of evidence was assessed by applying the GRADE methodology. The level of evidence for RCTs 
was downgraded due to moderate quality of the included RCTs (assessed by Cochrane risk bias tool for 
randomized studies), inconsistency attributed to endoscopists (eg, subjective assessments of lesion location 
and size) and patients (ie, different indications for  colonoscopy), and the imprecision due to possible 
differences in advanced adenoma definitions across studies. Details can be found in Supplementary Table 3. 
 
DISCUSSION 
The 44% and 70% relative increase in adenoma detection rate and adenoma per colonoscopy, 
consistently shown across the 5 included studies in nearly 4300 randomized patients, supports the benefit 
when adding CADe to colonoscopy with no meaningful effect on the efficiency of colonoscopy as shown by 
the similar withdrawal time between the 2 arms. 
The main result of our study is the independence between the additional benefit of CADe and the 
traditional features of colorectal neoplasia in the adequately powered subanalysis that were performed. In 
detail, CADe led to a statistically significant increase detection of both diminutive, small, and large 
adenomas, of those located in the proximal as well as in the distal colon, and of those flat and polypoid. In 
addition, there was an increase detection of SSL and a trend for a nearly 2-fold increase in advanced 
neoplasia. It could be argued that in previous pre-CADe studies neoplasia miss rate at colonoscopy was 
selectively associated with some of these features, such as flat morphology, proximal location, and 
diminutive to small size3. However, such evidence came from back-to-back studies, representing a markedly 
different methodology as the one adopted in the included RCTs3,6. In the tandem setting, miss rates from 
failure in lesion recognition and incomplete exposure of the mucosa are mixed, preventing a clear attribution 
of such miss rates to one or the other mechanism3,6. On the other hand, the CADe-RCT included in our meta-
analysis represents a parallel methodology where only failure to recognize the lesion contributes to the 
additional detection.  
The resilience of CADe efficacy from the traditional classifications of colorectal neoplasia is far 
from being unexpected as CADe and human perceptions are based on completely different mechanisms, 
namely a probabilistic analysis of the image based on training-acquired parameters vs human cognitive 
perception  that may be highly variable depending on training, experience, visual acuity, gaze patterns, and 
endoscopist personality. Thus, the finding that the additional CADe-driven detection is independent of 
features traditionally associated with missing suggests that characteristics other than size and morphology are 
exploited by the machine to recognize the lesion. Speculatively, these factors may be represented by the 
texture, color and shape factors other than those perceived by the human mind. 
 Despite the additional detection of adenomas >10 mm, our study failed to show an increase in the 
detection of advanced adenomas at a per patient or per polyp level. This discrepancy is unexpected 
considering that most of advanced adenoma pool is represented by >10 mm lesions. The authors of the 
Chinese studies did not respond to our requests for details regarding their definitions of advanced adenomas. 
Uncertainties regarding these definitions may have influenced the result we report here regarding advanced 
adenomas.  
There are limitations to our meta-analysis. Most of the analysis were performed at per polyp level, 
because per-patient data according to different features of lesions were not available. However, there is no 
reason to assume that the conversion between per patient and per polyp analysis would be different in the 2 
arms. Secondly, one of the adopted technology included both a CADe and an algorithm to improve other 
factors of quality of colonoscopy, such as the withdrawal technique or the level of cleansing. Unfortunately, 
such study did not allow to discriminate the possible impact of each of the 2 components, leaving uncertainty 
on the possible synergistic effect between CADe technology, on one side, and algorithms focusing on 
optimization of mucosa exposure during withdrawal, on the other. This limitation also applies to possible 
synergism between CADe and devices aiming to expose more mucosa, such as cup or endocuff, when 
considering that such devices were not used in the included studies. Thus, new studies specifically 
addressing the possible synergism between CADe and CAD technologies alarming the endoscopist when 
poorly exploring the mucosa are required.  In addition, we showed the additional efficacy of CADe for a 
variety of polyp categories according to size, morphology and histology. However, it is unclear how many of 
these categories were adequately represented in the training database. As the training database is the only 
clinical information that is fully transparent to endoscopist, any model should clearly report how many 
lesions for each category were included. Finally, the Chinese setting cannot be immediately translated with 
the Western setting, when considering the very low ADR in the control group of some of the studies that 
could depend on both a different prevalence of disease and operator skill The fact that CADe was successful 
in these studies with very low ADR in the control group could suggest an efficacy of CADe for low-
detectors. However, dedicated studies are needed. More in general, we could not properly assess the 
relationship between baseline ADR and CADe benefit. Thus, specific studies on both low- and high-
detectors are needed, as well as additional studies testing CADe in Western populations. 
In conclusion, lesion detection by AI is not impacted by factors such as size and morphology that are 
known to affect detection by human observers.  According to the current evidence, there is substantial and 
convergent evidence for the incorporation of Artificial Intelligence to increase detection of colorectal 
neoplasia during colonoscopy.  
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20 controlled clinical trial.pt.  93552  
21 pragmatic clinical trial.pt.  1301  
22 randomi#ed.tw.  606532  
23 placebo.ab.  205210  
24 clinical trials as topic/  190226  
25 randomly.ab.  327736  
26 (crossover or cross-over).tw.  83501  
27 Cross-over Studies/  47190  
28 trial.tw.  578824  
29 or/19-28  1508898  
30 animals/ not (humans/ and animals/)  4640785  
31 29 not 30  1383304  
32 18 and 31  347  
 




Search query Results 
1 colorectal AND ('adenoma'/exp OR adenoma)               24,082 
2 colorectal AND polyp$                               21,242   
3 adenomatous AND polyp$ 13,725   
4 #1 OR #2 OR #3                                      39,242   
5 'artificial intelligence'                            29,751   
6 'computer assisted diagnosis'                           38,416   
7 'computer-assisted'                                 836,274   
8 'cad':ab,ti                                              65,216   
9 'computer aided system'                              283 
10 'deep learning'                                     10,705   
11 #5 OR #6 OR #7 OR #8 OR #9 OR #10                      927,483   
12 #4 AND #11                                           1,841   
13 'randomized controlled trial'                           778,348   
14 'crossover procedure'                               62,131   
15 'double blind procedure'                            170,104   
16 'single blind procedure'                            37,978   
17 random*                                             1,721,357  
18 factorial*                                               38,617   
19 placebo*                                                455,566   
20 assign*                                                 387,430   
21 allocat*                                            163,890   
22 #13 OR #14 OR #15 OR #16 OR #17 OR #18 
OR #19 OR #20 OR #21     
2,283,452  
23 #12 AND #22 137 
  




Search query Results 
1 colorectal polyp in Trials  
(Word variations have been searched) 
1563  
2 colorectal adenoma in Trials  
(Word variations have been searched) 
1545 
3 colon adenoma in Trials  
(Word variations have been searched) 
1291 
4 adenomatous polyp in Trials  
(Word variations have been searched)/  
546 
5 #1 OR #2 OR #3 OR #4 2296  
6 artificial intelligence in Trials 412 
7 computer assisted in Trials 15848 
8 CAD in Trials 4775 
9 computer aided system in Trials 265  
10 deep learning in Trials 438 
11 #6 OR #7 OR #8 OR #9 OR #10 21207  
12 #5 AND #11 70  
 


















Control CAD Control CAD Control CAD Control CAD P value 




2 senior endoscopists (>20 000 colonoscopies) 
2 midlevel endoscopists (3000 to 10 000) 










6.1±1.1 6.2±1.4 ns 




4 senior endoscopists 
(> 5 years’ experience and  










6.4±1.1 6.5±1.3 ns 




6 experienced endoscopists  










7.0±1.5 7.1±1.5 ns 













6.1±1.0 6.2±1.3 ns 
















5.7±1.1 7.0±1.0 ns 
 







Adenoma  <5 mm (%) Adenoma   6-9 mm (%) 
Adenoma ≥10 mm 
(%) 
Adenoma proximal 
(%) Adenoma distal (%) 
Adenoma polypoid 
(%) 




























































































































































































































































Figure 1: Study selection flow chart. CADe: Computer-aided polyp detection.  
Figure 2: Comparative effectiveness of CAD versus control group on ADR. CAD: Computer-aided 
diagnosis. ADR: adenoma detection rate. 
Figure 3: Comparative effectiveness of CAD versus control group on APC subgrouped according to size. 
CAD: Computer-aided diagnosis. APC: adenoma per colonoscopy. 
Figure 4: Comparative effectiveness of CAD versus control group on APC subgrouped according to 







ACRONYMS and ABBREVIATIONS: 
Colorectal Cancer: CRC. 
Computer-Aided Polyp Detection: CADe. 
Randomized Clinical Trials: RCT. 
adenoma detection rate: ADR. 
Adenoma per colonoscopy: APC. 
Polyp per colonoscopy: PPC. 
Advanced  Adenoma per colonoscopy: AAPC. 
Polyp detection rate: PDR. 
Sessile serrated lesion per colonoscopy: SPC. 
Risk ratio: RR. 
Convoluted Neural Networks: CNN. 
Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: PRISMA. 
Sessile serrated lesions: SSL. 
Mean differences: MDs. 
Grades of Recommendation, Assessment, Development and Evaluation: GRADE. 
